

01 June 2018

Our Ref: RFI 23536

Dear

**Freedom of Information Act 2000
Request Regarding Biologics and Biosimilar Prescribing**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 17 May 2018.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled you have the right to seek a review within the Trust in the first instance. You should write to the: Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

V Smith (Miss)
Information Governance Assistant

RFI 23536

Appendix A

Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.

Number of patients treated	Rheumatology	Dermatology	Gastroenterology
TOTAL	588	168	316
Abatacept [Orencia]	17	0	0
Adalimumab [Biosimilar]	0	0	0
Adalimumab [Humira]	220	71	89
Apremilast [Otezla]	<10*	10	0
Baricitinib [Olumiant]	0	0	0
Brodalumab [Kyntheum]	0	0	0
Certolizumab [Cimzia]	<10*	0	0
Dimethyl fumarate [Skilarence]	0	0	0
Etanercept [Enbrel]	171	<10*	0
Etanercept Biosimilar [Benepali or Erelzi]	<10*	0	0
Golimumab [Simponi]	65	0	<10*
Guselkumab [Tremfya]	0	0	0
Infliximab [Remicade]	<10*	<10*	71
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]	<10*	<10*	101
Ixekizumab [Taltz]	0	<10*	0
Rituximab [Mabthera]	57	0	0
Rituximab Biosimilar [Rixathon or Truxima]	0	0	0
Sarilumab [Kevzara]	0	0	0
Secukinumab [Cosentyx]	14	35	0
Tocilizumab [Ro Actemra]	30	0	0
Tofacitinib [Xeljanz]	0	0	0
Ustekinumab [Stelara]	<10*	39	14
Vedolizumab [Entyvio]	0	0	33

*As you will note the data has been masked due to the small numbers within a small Geographical Area.